Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DMXL1 divergent transcript (DMXL1-DT) is a long non-coding RNA (lncRNA) gene, defined as a divergent transcript due to its orientation and location within 300–500 nucleotides of the protein-coding DMXL1 gene on chromosome 5. Divergent transcripts are a type of lncRNA, typically not translated into protein, and often participate in regulatory functions, usually for the expression of nearby genes[2][4][5]. There is currently no evidence that DMXL1-DT encodes a protein or is itself a therapeutic target, receptor, or druggable entity. All known disease and functional associations pertain to the protein-coding DMXL1 gene, not to DMXL1-DT. The DMXL1 divergent transcript (DMXL1-DT) is not a therapeutic target, nor is it a receptor, enzyme, transporter, or similar protein entity. Information on DMXL1-DT is limited, and most research and disease associations refer to DMXL1, a protein-coding gene. The entry "DMXL1 divergent transcript" may be incorrect as a target for drug discovery or pharmacology purposes[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DMXL1 divergent transcript (DMXL1-DT).